NCT07167446
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
Recruiting
EARLY_PHASE1Ages 18+InterventionalSupportive careFox Chase Cancer CenterInvestigator-initiated
~30 participants
Updated 2025-10-22 on ClinicalTrials.gov
What's tested:Cannabidiol (CBD)oxaliplatin-based chemotherapy
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of participants adherent to the CBD supplementation protocol at Week 12, as determined by pill counts, patient self-report, and clinic compliance logs.
Measured over Baseline through Week 12 of treatment
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Namrata Vijayvergia, MD · PRINCIPAL_INVESTIGATOR · Fox Chase Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants adherent to the CBD supplementation protocol at Week 12, as determined by pill counts, patient self-report, and clinic compliance logs.Baseline through Week 12 of treatment
- Acceptability of CBD supplementation as measured by the Feasibility of Intervention Measure (FIM)Baseline through Week 12 of treatment
5-point Likert scale, each item is scored 1-5. Higher scores = higher acceptability and feasibility of implementing the intervention